90 related articles for article (PubMed ID: 6785301)
1. Constancy of opioid control of luteinizing hormone in different pathophysiological states.
Lightman SL; Jacobs HS; Maguire AK; McGarrick G; Jeffcoate SL
J Clin Endocrinol Metab; 1981 Jun; 52(6):1260-3. PubMed ID: 6785301
[TBL] [Abstract][Full Text] [Related]
2. Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea.
Quigley ME; Sheehan KL; Casper RF; Yen SS
J Clin Endocrinol Metab; 1980 May; 50(5):949-54. PubMed ID: 6246138
[TBL] [Abstract][Full Text] [Related]
3. Correlation between integrated LH and FSH levels and the response to luteinizing hormone relasing factor (LRF).
Mortimer RH; Fleischer N; Lev-Gur M; Freeman RG
J Clin Endocrinol Metab; 1976 Dec; 43(6):1240-9. PubMed ID: 794076
[TBL] [Abstract][Full Text] [Related]
4. Alcohol effects on naloxone-stimulated luteinizing hormone, follicle-stimulating hormone and prolactin plasma levels in female rhesus monkeys.
Mello NK; Mendelson JH; Bree MP; Skupny A
J Pharmacol Exp Ther; 1988 Jun; 245(3):895-904. PubMed ID: 3133465
[TBL] [Abstract][Full Text] [Related]
5. Evidence for an increased opioid inhibition of luteinizing hormone secretion in hyperprolactinemic patients with pituitary microadenoma.
Quigley ME; Sheehan KL; Casper RF; Yen SS
J Clin Endocrinol Metab; 1980 Mar; 50(3):427-30. PubMed ID: 7358828
[TBL] [Abstract][Full Text] [Related]
6. Naloxone increases the frequency of pulsatile luteinizing hormone secretion in women with hyperprolactinemia.
Cook CB; Nippoldt TB; Kletter GB; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1991 Nov; 73(5):1099-105. PubMed ID: 1939525
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
[TBL] [Abstract][Full Text] [Related]
8. Effects of naloxone on prolactin-secreting pituitary adenomas.
Shima K; Chigasaki H; Seki K
Neurol Med Chir (Tokyo); 1990 Feb; 30(2):109-12. PubMed ID: 1695330
[TBL] [Abstract][Full Text] [Related]
9. The effect of naloxone on endogenous opioid regulation of pituitary gonadotropins and prolactin during the menstrual cycle.
Snowden EU; Khan-Dawood FS; Dawood MY
J Clin Endocrinol Metab; 1984 Aug; 59(2):298-302. PubMed ID: 6330154
[TBL] [Abstract][Full Text] [Related]
10. Naloxone does not interfere with the dopamine-induced decrease in gonadotropin secretion in women with polycystic ovarian disease.
Paradisi R; Margrini O; Venturoli S; Fabbri R; Porcu E; Stanzani L; Flamigni C
Horm Metab Res; 1985 Jan; 17(1):29-31. PubMed ID: 3917966
[TBL] [Abstract][Full Text] [Related]
11. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation.
Barnes RB; Lobo RA
J Clin Endocrinol Metab; 1985 Oct; 61(4):779-82. PubMed ID: 3928677
[TBL] [Abstract][Full Text] [Related]
12. The role of endogenous opiates in the mechanism of inhibited luteinizing hormone (LH) secretion in women with anorexia nervosa: the effect of naloxone on LH, follicle-stimulating hormone, prolactin, and beta-endorphin secretion.
Baranowska B; Rozbicka G; Jeske W; Abdel-Fattah MH
J Clin Endocrinol Metab; 1984 Sep; 59(3):412-6. PubMed ID: 6086696
[TBL] [Abstract][Full Text] [Related]
13. Differences in the opioid control of luteinizing hormone secretion between pathological and iatrogenic hyperprolactinemic states.
Petraglia F; De Leo V; Nappi C; Facchinetti F; Montemagno U; Brambilla F; Genazzani AR
J Clin Endocrinol Metab; 1987 Mar; 64(3):508-12. PubMed ID: 2880862
[TBL] [Abstract][Full Text] [Related]
14. Opioid peptides in pseudocyesis.
Devane GW; Vera MI; Buhi WC; Kalra PS
Obstet Gynecol; 1985 Feb; 65(2):183-8. PubMed ID: 3918282
[TBL] [Abstract][Full Text] [Related]
15. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
Prelević GM; Würzburger MI; Perić LA
J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
[TBL] [Abstract][Full Text] [Related]
16. Effects of calcitonin on basal and thyrotropin-releasing hormone-stimulated prolactin secretion in man.
Isaac R; Merceron R; Caillens G; Raymond JP; Ardaillou R
J Clin Endocrinol Metab; 1980 Jun; 50(6):1011-5. PubMed ID: 6768762
[TBL] [Abstract][Full Text] [Related]
17. Hormone ontogeny in the ovine fetus: XIV. The effect of 17 beta-estradiol infusion on fetal plasma gonadotropins and prolactin and the maturation of sex steroid-dependent negative feedback.
Gluckman PD; Marti-Henneberg C; Kaplan SL; Grumbach MM
Endocrinology; 1983 May; 112(5):1618-23. PubMed ID: 6403330
[TBL] [Abstract][Full Text] [Related]
18. Naloxone interaction with pituitary response to TRH and LHRH test in patients with polycystic ovary syndrome.
Micić D; Popović V; Minić S; Sumarac M; Kendereski A; Damjanović S; Manojlović D; Mićić J
Endocrinol Exp; 1990 Mar; 24(1-2):187-93. PubMed ID: 2113856
[TBL] [Abstract][Full Text] [Related]
19. The effects of estrogen and progesterone on the functional capacity of the gonadotrophs.
Lasley BL; Wang CF; Yen SS
J Clin Endocrinol Metab; 1975 Nov; 41(5):820-6. PubMed ID: 1102551
[TBL] [Abstract][Full Text] [Related]
20. Calcium antagonists and hormone release. II. Effects of verapamil on basal, gonadotropin-releasing hormone- and thyrotropin-releasing hormone-induced pituitary hormone release in normal subjects.
Barbarino A; De Marinis L
J Clin Endocrinol Metab; 1980 Oct; 51(4):749-53. PubMed ID: 6774993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
